. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2020 Dec 22:S0360-3016(20)34356-X. doi: 10.1016/j.ijrobp.2020.09.054

Table 2.

Selected studies analyzing factors associated with late bowel side effects

Study	n	Treatment details	Med. f/u (yrs)	Bowel endpoint	Dosimetric factors associated^* with worse bowel outcomes	Non-dosimetric factors associated^* with worse bowel outcomes
King 2012²⁰ (Stanford)	67	36.25 Gy (5 fx), QD/QOD	2.7	RTOG G2: 2.0%		QD (vs. QOD) treatment schedule
Kim 2014³³ (Multicenter)	91	16%:45 Gy (5 fx), QOD 16%: 47.5 Gy (5 fx), QOD 67%: 50 Gy (5 fx), QOD	2.0	CTCAE v3 G2:23.1% G3:3.3% G4: 2.2%	Rectum V50Gy > 3 cc Rectum Circumference V39Gy > 35%
Elias 2014²² (Sunnybrook)	84	35 Gy (5 fx), QW	4.2	EPIC QOL MID: 26.2%	Rectum V31.8Gy > 10% Rectum D1cc > 35 Gy
Gomez 2015²⁶ (UCLA)	75	40 Gy (5 fx), QOD	1.0	EPIC QOL	Rectum V40Gy > 1.5 cc Rectum V36Gy > 4.2 cc
Musunuru 2016³⁴ (Sunnybrook)	258	33%: 35 Gy (5 fx), QW 67%: 40 Gy (5 fx), QW or QOD	2.5	CTCAE v3 G2 bleed: 16.2% G3 bleed: 1.6% G4 bleed: 1.6%	Rectum V38Gy > 2 cc Prescription dose 40 Gy (vs. 35 Gy)	SV treatment (vs. prostate only) PTV margin 5mm (vs. 4mm) Hemorrhoids Anticoagulant use
Miszczyk 2017³⁵ (Gliwice)	400	36.25 Gy (5 fx), QOD	1.3	RTOG G1:4.7% G2: 0.6% G3: 0.3%		Diabetes

Abbreviations: QW; every week, QOD; every other day, QD; every day, MID; minimally important difference, SV; seminal vesicle.

Included if reported as trend or significant on univariate or multivariate analysis